Medicaid is calling on states to enhance oversight of autism therapy services due to a dramatic increase in spending. The program's expenditure on these therapies has quintupled since 2021, a growth rate that far exceeds the rise in autism diagnoses.

This rapid escalation has triggered concerns among federal health officials about the potential for overprescribing of services and fraudulent billing practices. The Centers for Medicare & Medicaid Services (CMS) has issued guidance to state Medicaid agencies, urging them to implement stricter measures to ensure the appropriate and effective use of these therapies.

The guidance emphasizes the need for states to review provider qualifications, monitor treatment plans, and verify the medical necessity of services. These steps are intended to protect beneficiaries and ensure that taxpayer dollars are spent efficiently and ethically, preventing both waste and abuse within the system.